All Blogs
Apr 16, 2026
Reach Surgical Announces CE Mark Certification for Innovative iREACH IRIS Stapling System; TOBY Earns FDA Breakthrough Tag for Innovative Urine-Based Cancer Detection Test; DuPont Introduces AmberChrom™ XT SL Resins to Streamline Biopharma Processing; Sectra Strengthens AI Roadmap with Completion of Oxipit Acquisition; KingstronBio Marks First Patient Implant of ProStyle M® in National Multicenter Study; MiRus Starts Recruiting Patients for STAR Trial Evaluating Siegel™ Valve
Reach Surgical Received CE Mark Approval for iREACH IRIS, First Powered Reusable Stapler with Real-Time Firing Curve™ and 90° Articulation On 14 April 2026, Reach Surgical, the surgical solutions division of Genesis MedTech, received CE Mark approval for its next-generation powered stapling platform, iREACH IRIS...
Read More...
Apr 15, 2026
8 Key Applications of Radioligand Therapies in Healthcare
The global healthcare industry is transforming precision medicine and targeted therapies redefine the way complex diseases, especially cancer, are treated. One of the most promising innovations emerging from nuclear medicine is Radioligand Therapies (RLTs), a treatment modality that combines molecular targeting wit...
Read More...
Apr 14, 2026
IDEAYA and Servier Reports Successful Uveal Melanoma Trial; SynOx Therapeutics Highlights Positive Phase 3 TANGENT Topline Data; Regeneron and Telix Ink Strategic Radiopharma Deal; GSK Shares Promising Clinical Data on B7-H4-Targeted ADC; Replimune’s RP1 Hits Regulatory Hurdle with FDA Complete Response Letter
IDEAYA Biosciences and Servier Advance Darovasertib Program with Positive Registrational Trial Results IDEAYA Biosciences and Servier have announced positive topline findings from the Phase 2/3 OptimUM-02 registrational trial evaluating the combination of darovasertib and crizotinib. The study targeted patients ...
Read More...
Apr 13, 2026
Novartis Bets Big on Radioligand Therapy with Multiple Pipeline Candidates and Expanding Trials
Summary With FDA-approved products LUTATHERA and PLUVICTO, both beta-emitters, Novartis has established itself as an industry frontrunner. Over 15 ongoing or planned trials and several next-generation candidates in development in Novartis RLT pipeline. Rivals include AstraZeneca, Bayer, Eli Lilly, C...
Read More...
Apr 10, 2026
5 Emerging Polycythemia Vera Therapies Eyeing Market Dominance
Summary Three drugs that have been approved for PV include JAKAFI/JAKAVI (ruxolitinib), BESREMi (ropeginterferon alfa-2B/AOP2014/P1101), and PEGASYS (peginterferon alfa-2a). JAKAFI and BESREMi are approved in the US, Europe, and Japan, while PEGASYS is approved only in Europe. JAKAFI is nearing its pat...
Read More...
Apr 09, 2026
Waters Receives FDA Approval for Advanced HPV Self-Collection and Testing Kit; MedCAD Achieves FDA 510(k) Clearance for AccuStride® Tib/Fib Anatomical Solution; Mercy Medical Center Expands IBD Care with Office-Based Intestinal Ultrasound; BD Introduced Next-Generation TIPS Innovation to Enhance Portal Hypertension Care in the European Union; KingstronBio Completes First ProStyle M® Mitral Valve Implant in Confirmatory Trial; MiRus Launches Enrollment for STAR Randomized Study of Siegel™ TAVR System
Waters Announced the FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay On 08 April 2026, Waters Corporation announced that the U.S. Food and Drug Administration had cleared the Onclarity HPV Self-Collection Kit and app...
Read More...
Apr 08, 2026
Acute Ischemic Stroke Treatment and Diagnosis Devices: Technologies Transforming Stroke Care
Stroke remains one of the most critical challenges in modern medicine, representing a leading cause of long-term disability and mortality worldwide. According to the World Health Organization (WHO), stroke is responsible for approximately 11% of total deaths globally. Within this landscape, Acute Ischemic Stroke (A...
Read More...
Apr 07, 2026
Neurocrine Signs Deal to Acquire Soleno Therapeutics; AstraZeneca Shares Favorable Results from EMERALD-3 Study in Liver Cancer; Immunovant Presents Phase 3 Clinical Data for Batoclimab in TED; Alto Neuroscience Shares Topline Findings from Phase 2 ALTO-101 Study and Pipeline Updates; ORIC Positions Rinzimetostat for Phase 3 Success with Optimized Dosing Strategy
Neurocrine Announces Acquisition of Soleno Therapeutics to Broaden Rare Disease Portfolio Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics in a transaction valued at approximately $2.9 billion, marking a significant strategic expansion into the rare disease and metabo...
Read More...
Apr 06, 2026
Unlocking Growth Potential in the Presbyopia Treatment Market: Innovations Reshaping Age-Related Vision Loss
Summary According to DelveInsight’s analysis, in 2025, the total prevalent cases of presbyopia were approximately 280.5 million cases in the 7MM. The total number of diagnosed cases of presbyopia was approximately 235 million cases. A significant proportion of presbyopia patients, nearly 65%, continue to rel...
Read More...
Apr 03, 2026
Tenosynovial Giant Cell Tumor Treatment Landscape: A Dual-Modality Race Targeting CSF1R
Summary According to DelveInsight’s estimates, nearly 580,000 prevalent cases of TGCT were reported across the 7MM in 2025, with approximately 460,000 cases classified as localized TGCT and nearly 120,000 as diffuse TGCT; these subtypes differ notably in clinical presentation, recurrence rates, and overall dise...
Read More...